In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
A Strategic Business Plan to ensure success under MDR/IVDR
David Novotny and Angela Brown share their insights in this Medical Design and Outsourcing article as to how manufacturers can develop a strategic business model that will prepare them for success under the new MDR/IVDR reforms
-
-
Trends in Biosimilar Market Access
A thought leadership article authored by Jenny Lee and Gene Chieh, investigating how biosimilars have gained momentum in a growing number of markets.
-
Biomarker-driven Landscape in Clinical Trials
ICON's Nicole Cowan is interviewed in the latest edition of Clinical OMICs about the new biomarker-driven landscape in clinical trials and the nuances of drug-diagnostics co-development programs.
-
Social Media Outreach
ICON expert Gretchen Goller considers social media outreach's beneficial effect on patient connectivity to date in the October 2019 edition of Pharma Voice.
-
Making it Easier for the Site to Succeed
A thought leadership article authored by EB McLindon, discussing how making clinical research easier for the site can also make life easier for sponsors.
-
-
ICON to Offer At-Home Clinical Trials following Symphony Purchase
ICON boosts its hybrid clinical trial and site support services with the acquisition of Symphony Clinical Research, a provider of in-home and alternate site services.
-
Alzheimer’s in Clinical Trials – Is There a Way Out of Ongoing Failures?
A thought leadership article authored by Peter Schueler, exploring how the series of failures in Alzheimer’s disease research has provided insights into the disease pathology, study methodologies and - as a consequence – in the design of future development programmes for anti-Alzheimer medications.
-
Validating Value Data: AI & Outcomes
The application of AI and machine learning in establishing a treatment’s value proposition is still a relatively new concept in pharma. Katya Svoboda, Taneesha Chawla, and Tanvi Ahuja, authors of the ICON whitepaper, The Impact of Artificial Intelligence on Outcomes Based Contracting discuss the challenges and opportunities in the October 2019
